Drug Search Results
More Filters [+]

64Cu-SAR-bisPSMA

Alternative Names: 64Cu-SAR-bisPSMA
Latest Update: 2024-10-16
Latest Update Note: News Article

Product Description

Mechanisms of Action: Imaging Agent

Novel Mechanism: No

Modality: Diagnostic Agent

Route of Administration: Injection

FDA Designation: Fast Track - Oncology *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Cleave Biosciences
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for 64Cu-SAR-bisPSMA

Countries in Clinic: Australia, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Prostate Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SECuRE

P2

Recruiting

Prostate Cancer

2026-09-01

CLARIFY

P3

Recruiting

Prostate Cancer

2025-02-01

COBRA

P2

Completed

Prostate Cancer

2023-08-08

PROPELLER

P1

Completed

Prostate Cancer

2022-10-19

Recent News Events